Company intelligence / Profile preview

Xeltis

Eindhoven, North Brabant, Netherlandsxeltis.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Xeltis' aXess vascular access graft is in pivotal clinical trials, with encouraging preliminary human data. The company’s ETR platform has also advanced pulmonary heart valve and coronary artery bypass graft programs into the clinic. Early results suggest the implants are well-tolerated and promote natural tissue regeneration, potentially reducing complications like thrombosis, stenosis, calcification, and infection.

Therapeutic areas: CardiovascularNephrology
Modalities: DevicePolymer-based implantBiologic
Industry: Implantable Medical Devices

Drug pipeline

1 asset

aXess

Phase 3

Indications: Hemodialysis vascular access

Partnerships

No major pharma partnerships disclosed as of June 2025. Investors include DaVita Venture Group and Grand Pharma Group among others

Beyond the preview

Go deeper on Xeltis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xeltis.

Explore the full profile